View Abstract #5003 :
Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

View Abstract #5004 :
A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer.

View Abstract #5005 :
A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer.

View Abstract #LBA5006 :
Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.

View Abstract #LBA5007 :
OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), ...

View Abstract #5008 :
Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT).

View Abstract #5009 :
A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma.

View Abstract #5010 :
A comparative randomized, placebo-controlled, double-blind phase II study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment for advanced ovarian c...

View Abstract #5011 :
A phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC).